Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) shares shot up 3.9% during trading on Thursday. The stock traded as high as $3.46 and last traded at $3.46. Approximately 362,350 shares were traded during mid-day trading, an increase of 39% from the average session volume of 261,100 shares. The stock had previously closed at $3.33.
Aadi Bioscience Stock Performance
The firm has a market capitalization of $85.45 million, a PE ratio of -1.52 and a beta of 0.68. The company’s fifty day moving average price is $3.92 and its two-hundred day moving average price is $3.81.
About Aadi Bioscience
Aadi Bioscience, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with genetically defined cancers. The company’s primary product is FYARRO (sirolimus protein-bound particles for injectable suspension), an albumin-bound formulation of sirolimus designed to deliver an mTOR inhibitor to tumors.
FYARRO received approval from the U.S. Food and Drug Administration in 2021 for the treatment of adults with advanced unresectable or metastatic malignant perivascular epithelioid cell tumors, or PEComa, who require systemic therapy.
Read More
- Five stocks we like better than Aadi Bioscience
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
